FibroBiologics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
FBLG Nasdaq 2830 fibrobiologics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for FibroBiologics, Inc.

FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets - Aug 11th, 2026 6:30 am
FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage - Aug 5th, 2026 6:30 am
FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate - Jul 31st, 2026 3:34 pm
FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors - Jul 9th, 2026 6:30 am
FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial - Jul 7th, 2026 6:30 am
FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - Jun 30th, 2026 6:30 am
FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules - Jun 29th, 2026 2:01 pm
FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules - Jun 26th, 2026 6:30 am
FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing - Jun 22nd, 2026 6:30 am
FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers - Jun 16th, 2026 6:30 am
FBLG: Phase 1/2 Trial of CYWC628 Underway - Jun 4th, 2026 4:02 am
FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers - Jun 3rd, 2026 5:00 am
EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial - Jun 3rd, 2026 4:46 am
Is FibroBiologics, Inc. (FBLG) Advancing Toward a Breakthrough Psoriasis Treatment With CYPS317 Data? - Jun 2nd, 2026 7:57 am
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting - May 22nd, 2026 6:30 am
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics - May 18th, 2026 6:30 am
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus - May 11th, 2026 6:30 am
FibroBiologics CEO Issues Letter to Shareholders - May 5th, 2026 6:30 am
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring - May 4th, 2026 2:01 pm
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial - May 4th, 2026 6:30 am